Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial and in rhesus monkeys
1142  

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial and in rhesus monkeys

The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys, and it provided significant protection against repetitive heterologous SHIV challenges in rhesus monkeys. This vaccine concept is currently being evaluated in a phase 2b clinical efficacy study ...

July 09, 2018
News  
Implants for Delivery of Antiretroviral Drugs for HIV Pre-Exposure Prophylaxis
878  

Implants for Delivery of Antiretroviral Drugs for HIV Pre-Exposure Prophylaxis

Strategies to reduce new HIV infections span multifaceted efforts, including safe-sex counseling, voluntary medical male circumcision, treatment as prevention, and pre- (PrEP) and postexposure prophylaxis. PrEP entails the use of antiretroviral (ARV) drugs prophylactically by HIV-negative individuals at risk of infection to thwart acquisition of ...

June 21, 2018
News  
San Francisco and Oakland to host AIDS 2020
990  

San Francisco and Oakland to host AIDS 2020

The International AIDS Society (IAS) has announced that San Francisco, California, in partnership with nearby Oakland, will host the 23rd International AIDS Conference (AIDS 2020). This is 30 years after the event was held there at the height of the epidemic in the United States. ...

June 21, 2018
News  
Michel Kazatchkine as the new Chair of Board of AFEW
956  

Michel Kazatchkine as the new Chair of Board of AFEW

Between 2007 and 2012, Professor Michel Kazatchkine has been the executive Director of the Global Fund to fight AIDS, Tuberculosis and malaria. From 2012 to 2017, he served as the UN Secretary General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia. He is ...

June 20, 2018
News  
Many young MSM discontinue PrEP
1196  

Many young MSM discontinue PrEP

A third of young men who have sex with men (MSM) discontinue pre-exposure prophylaxis (PrEP) within a six-month period, investigators from the United States report in AIDS and Behavior. Common reasons for stopping included being unable to get an appointment with a doctor and problems ...

June 04, 2018
AIDSmap  News